Holen Sie sich die Stockscreener-App
52.70
8.68%
-5.01
Handel nachbörslich:
52.69
-0.01
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$57.71
Offen:
$56.39
24-Stunden-Volumen:
2.64M
Relative Volume:
1.12
Marktkapitalisierung:
$7.29B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-37.91
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+30.28%
1M Leistung:
+33.25%
6M Leistung:
+238.69%
1J Leistung:
+101.53%
1-Tages-Spanne:
$52.08
$56.67
1-Wochen-Bereich:
$40.43
$59.15
52-Wochen-Spanne:
$9.57
$59.15
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
52.70 | 7.84B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead (ARWR) Shares Drop Over 8% in Recent Trading - GuruFocus
Is Arrowhead Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Minimal Capital Trading - earlytimes.in
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead: Gains Make Mockery Of My Sell CallBut Jury May Still Be Out (Rating Upgrade) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (HDP1.F) stock price, news, quote and history - Yahoo Finance UK
Arrowhead Pharmaceuticals Reports Transformative Year-End Results - MSN
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval - Finviz
Morgan Stanley Maintains Arrowhead Pharmaceuticals (ARWR) Equal-Weight Recommendation - MSN
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy - Yahoo Finance
Arrowhead Pharmaceuticals Hits Day High with 9.42% Surge in Stock Price - Markets Mojo
Arrowhead Pharmaceuticals at Risk: Potential Generic Competition Threatens REDEMPLO’s Market Exclusivity - TipRanks
10 Big Names Feasting on Gains Ahead of Thanksgiving - Insider Monkey
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals’ Earnings Call Highlights FDA Approval and Strong Financials - TipRanks
Arrowhead Pharmaceuticals Reports Record Revenue and FDA Approvals - StocksToTrade
Arrowhead’s Triumph: A New Dawn? - timothysykes.com
How (ARWR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026 - MSN
Arrowhead Pharmaceuticals: Hold Rating Amid Redemplo Launch and Financial Stability - TipRanks
Arrowhead (ARWR) Shares Surge Over 23% - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Arrowhead Pharmaceuticals Takes Significant Strides with FDA Approval Boosting Market Confidence - timothysykes.com
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Morgan Stanley Raises Price Target for ARWR to $48.00 | ARWR Sto - GuruFocus
Arrowhead (ARWR) Shares Surge by 9% - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $46.89 - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals : ARWR FQ4 2025 Script Final - MarketScreener
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals Q4 2025 sees stock surge - Investing.com Australia
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Achieves FDA Approval for REDEM - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... - Yahoo Finance
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q4 2025 Earnings Conference - 富途牛牛
Why Shares in Arcutis Biotherapeutics Surged Again This Week - AOL.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Arrowhead (ARWR) Q4 2025 Earnings Call Transcript - AOL.com
Arrowhead Pharmaceuticals (ARWR) Stock: Soars Following Strong Financial Performance and FDA Approval - parameter.io
Arrowhead Pharmaceuticals (ARWR) Surpasses Revenue Estimates wit - GuruFocus
Arrowhead Pharmaceuticals Fiscal-Year Loss Narrows, Revenue Rises - MarketScreener
Arrowhead (ARWR) Surpasses Revenue Expectations with FDA Approva - GuruFocus
Arrowhead reports FY25 EPS (1c), consensus (3c) - TipRanks
ARROWHEAD PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - MarketScreener
[8-K] ARROWHEAD PHARMACEUTICALS, INC. Reports Material Event | ARWR SEC FilingForm 8-K - Stock Titan
Arrowhead Pharmaceuticals Hits New 52-Week High of $44.80 - Markets Mojo
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Arrowhead Pharmaceuticals FQ4 2025 Earnings Preview - MSN
ARWR Stock: Arrowhead Pharmaceuticals Hits New High as FDA Approval and Q4 Earnings Converge - ts2.tech
Arrowhead Pharmaceuticals (ARWR) Awaits FQ4 Earnings Amid Recent FDA Approval - GuruFocus
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):